viewProactive Group

BrightHouse rapped by FCA and agrees to repay £14.8mln

BrightHouse has identified two historic issues that have led to it making repayments to some customers. These issues relate to the refund of first payments for cancelled agreements and the effectiveness of affordability checks

BrightHouse FCA statement
Buying items on hire purchase can work out very expensive in the long run

Electricals retailer BrightHouse has been instructed by the Financial Conduct Authority (FCA) to cough up £14.8mln to customers who were mis-sold items “on tick”.

Some 249,000 customers who are waiting for refunds after cancelling agreements during the “cooling off” period after purchase will be recompensed by BrightHouse.

The FCA said BrightHouse had not acted as a “responsible lender”, lending money to customers who were most unlikely to be able to afford the monthly payments.

BrightHouse has apologised to customers and said it had “identified customers that may have been treated unfairly where its processes fell short of FCA expectations”.

BrightHouse working with the FCA since 2014

Jonathan Davidson, executive director of supervision at the FCA, said he was pleased that BrightHouse had agreed to provide redress to those customers affected by the retailer’s iffy loans procedures.

BrightHouse has been working with the FCA since 2014 to get its house in order after the watchdog expressed alarm at the retailer’s lending assessment and collections processes.

“This [redress] scheme continues our work with the rent-to-own sector to resolve the concerns we have previously identified.

“Responsible lending and the fair treatment of consumers, especially those in financial difficulties or who are vulnerable, are key priorities for us,” Davidson said.


Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Mountain Valley MD to start husbandry animal trials to validate company’s...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company is planning to start husbandry animal trials with a third-party research organization to validate injectable solubilized Ivermectin...

2 minutes ago

2 min read